MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-07-25T16:54:00Z
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Tue 23 Jul 24, 01:40 PM3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
Thu 18 Jul 24, 12:00 AMJ&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
Wed 17 Jul 24, 03:27 PMBig Money Eyes Halozyme for Strong Growth
Tue 16 Jul 24, 09:11 PM3 Biotech Stocks to Buy Now: Q3 Edition
Mon 15 Jul 24, 12:00 AMTop Medical Stocks to Buy for Growth & Performance
Wed 10 Jul 24, 09:00 PMHow to Find Strong Buy Medical Stocks Using the Zacks Rank
Wed 10 Jul 24, 01:40 PMIf You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Wed 10 Jul 24, 12:30 PMIs Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Tue 09 Jul 24, 04:45 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 248.92M | 248.52M | 129.30M | -72.25100M | -79.79300M |
| Minority interest | - | - | - | - | - |
| Net income | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
| Selling general administrative | 143.53M | 50.32M | 45.74M | 77.25M | 60.80M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 520.81M | 361.90M | 224.23M | 150.45M | 141.73M |
| Reconciled depreciation | 49.64M | 3.00M | 3.28M | 4.07M | 2.39M |
| Ebit | 267.53M | 272.90M | 140.97M | -71.67800M | -71.71800M |
| Ebitda | 310.68M | 275.90M | 144.25M | -67.61000M | -69.33000M |
| Depreciation and amortization | 43.15M | 3.00M | 3.28M | 4.07M | 2.39M |
| Non operating income net other | -1.66600M | -19.85800M | 5.42M | 6.99M | 7.58M |
| Operating income | 267.53M | 275.90M | 144.25M | -67.61000M | -69.33000M |
| Other operating expenses | 392.58M | 167.41M | 123.34M | 263.60M | 221.19M |
| Interest expense | 16.95M | 7.53M | 20.38M | 11.63M | 18.04M |
| Tax provision | 46.79M | -154.19200M | 0.22M | -0.01100M | 0.54M |
| Interest income | - | - | - | 4.64M | 10.46M |
| Net interest income | -16.94700M | -7.52600M | -20.37800M | -11.62700M | -18.04100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 46.79M | -154.19200M | 0.22M | -0.01100M | 0.54M |
| Total revenue | 660.12M | 443.31M | 267.59M | 195.99M | 151.86M |
| Total operating expenses | 253.28M | 86.00M | 79.97M | 218.06M | 211.06M |
| Cost of revenue | 139.30M | 81.41M | 43.37M | 45.55M | 10.14M |
| Total other income expense net | -18.61300M | -27.38400M | -14.95300M | -4.64100M | 7.58M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
| Net income applicable to common shares | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1733.27M | 1841.51M | 1104.43M | 579.92M | 565.87M |
| Intangible assets | 472.88M | 546.65M | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 48.61M | 45.02M | 40.48M | 28.27M | 33.37M |
| Total liab | 1649.46M | 1671.71M | 907.48M | 428.88M | 474.11M |
| Total stockholder equity | 83.81M | 169.80M | 196.95M | 151.05M | 91.77M |
| Deferred long term liab | - | - | - | - | 2.49M |
| Other current liab | 100.68M | 96.52M | 24.44M | 20.48M | 55.65M |
| Common stock | 0.13M | 0.14M | 0.14M | 0.14M | 0.14M |
| Capital stock | 0.13M | 0.14M | 0.14M | 0.14M | 0.14M |
| Retained earnings | 90.55M | 143.22M | -58.91200M | -474.59300M | -603.67800M |
| Other liab | - | 17.73M | 3.07M | 7.49M | 2.31M |
| Good will | 416.82M | 409.05M | - | - | - |
| Other assets | - | 71.23M | 169.35M | 14.57M | 11.58M |
| Cash | 118.37M | 234.19M | 118.72M | 147.70M | 120.18M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 112.49M | 130.79M | 117.15M | 421.38M | 85.64M |
| Current deferred revenue | -32.19700M | 3.25M | 1.75M | 1.75M | 4.01M |
| Net debt | 1380.88M | 1271.90M | 757.96M | 249.53M | 282.41M |
| Short term debt | 32.20M | 13.33M | 89.42M | 397.23M | 19.54M |
| Short long term debt | - | 13.33M | 89.42M | 397.23M | 19.54M |
| Short long term debt total | 1499.25M | 1506.10M | 876.67M | 397.23M | 402.59M |
| Other stockholder equity | 2.41M | 27.37M | 256.35M | 625.48M | 695.07M |
| Property plant equipment | - | 75.57M | 8.79M | 10.59M | 10.86M |
| Total current assets | 746.42M | 739.01M | 926.29M | 554.76M | 543.44M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -783.65000M | 196.95M | 155.07M | 90.52M |
| Short term investments | 217.63M | 128.60M | 622.20M | 220.31M | 301.08M |
| Net receivables | 234.21M | 231.07M | 90.97M | 97.73M | 59.44M |
| Long term debt | 1499.25M | 1492.77M | 787.25M | - | 383.05M |
| Inventory | 127.60M | 100.12M | 53.91M | 60.75M | 29.36M |
| Accounts payable | 11.82M | 17.69M | 1.54M | 1.93M | 6.43M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -9.27800M | -0.92200M | -0.62000M | 0.02M | 0.24M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.14M | 0.14M | 0.14M | 0.14M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 143.22M | -58.91200M | -474.59300M | -603.67800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 17.82M | 26.80M | 13.91M | 14.57M | 11.58M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 986.85M | 1102.50M | 178.14M | 25.16M | 22.44M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 1492.77M | 787.25M | - | 383.05M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 490.92M | -404.83200M | 79.78M | -1.50900M | 7.16M |
| Change to liabilities | 24.54M | 1.17M | -36.57600M | 4.64M | 8.70M |
| Total cashflows from investing activities | -487.00500M | -406.28900M | 78.35M | -5.54900M | 2.49M |
| Net borrowings | 617.44M | 415.81M | -19.56000M | 338.99M | -77.51600M |
| Total cash from financing activities | 362.37M | 77.86M | -106.28400M | 153.22M | -63.79700M |
| Change to operating activities | -9.06400M | -11.55500M | 2.52M | -19.00600M | -5.69500M |
| Net income | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
| Change in cash | 115.48M | -28.98400M | 27.52M | 62.24M | -110.80400M |
| Begin period cash flow | 119.22M | 148.20M | 120.68M | 58.44M | 169.24M |
| End period cash flow | 234.69M | 119.22M | 148.20M | 120.68M | 58.44M |
| Total cash from operating activities | 240.11M | 299.44M | 55.45M | -85.42300M | -49.50000M |
| Issuance of capital stock | - | - | - | 0.00000M | 0.00000M |
| Depreciation | 49.64M | 3.00M | 3.28M | 4.07M | 2.39M |
| Other cashflows from investing activities | -973.11400M | - | 1.08M | -1.50900M | 7.16M |
| Dividends paid | - | -12.53600M | -63.39300M | -14.22400M | - |
| Change to inventory | -17.48100M | 7.37M | -31.38800M | -6.73400M | -17.48000M |
| Change to account receivables | -83.94100M | 6.75M | -38.28800M | -29.43700M | 11.61M |
| Sale purchase of stock | -200.00200M | -350.05800M | -150.11700M | -199.99800M | 13.72M |
| Other cashflows from financing activities | 995.78M | 796.99M | 63.39M | 461.30M | 2.49M |
| Change to netincome | 67.02M | -113.64700M | 16.42M | 36.14M | 35.69M |
| Capital expenditures | 4.81M | 1.46M | 2.50M | 4.04M | 4.66M |
| Change receivables | -83.94100M | 6.75M | -38.28800M | -29.43700M | 11.61M |
| Cash flows other operating | -10.73400M | -13.80200M | -2.05700M | -17.87900M | -5.69500M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 115.48M | -28.98400M | 27.52M | 62.24M | -110.80400M |
| Change in working capital | -85.95100M | 3.74M | -108.36600M | -50.53900M | -5.86600M |
| Stock based compensation | 24.40M | 20.82M | 17.20M | 34.78M | 35.70M |
| Other non cash items | 9.89M | 24.61M | 13.60M | -1.97800M | 1.70M |
| Free cash flow | 235.30M | 297.98M | 52.95M | -89.46300M | -54.16300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics Inc |
1.21 2.19% | 56.36 | 18.18 | 12.63 | 5.92 | 58.55 | 7.32 | 13.43 |
| NVO Novo Nordisk A/S |
-2.29 1.74% | 129.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.80 2.90% | 135.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.67 0.75% | 494.48 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
22.92 2.16% | 1083.78 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
12390 El Camino Real, San Diego, CA, United States, 92130
| Name | Title | Year Born |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | Pres, CEO & Director | 1963 |
| Dr. Michael J. LaBarre Ph.D. | Chief Technical Officer | 1964 |
| Ms. Nicole LaBrosse | CFO & Director | 1983 |
| Ms. Tram Bui | VP of Investor Relations & Corp. Communications | NA |
| Mr. Mark Snyder Esq. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | NA |
| Ms. Amy Marinne Fox | Chief HR Officer | NA |
| Dr. Steve Knowles MBBS | Chief Medical Officer | NA |
| Mr. Todd Butler | Chief of Staff to the CEO, VP & Head of Project Management | NA |
| Dr. Christopher Bryant Ph.D. | Chief Manufacturing Officer & Head of Technical Operations | 1961 |
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...